---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-004313"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T01:15:34.292048+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arrowhead appoints Sarepta CEO Douglas Ingram as director

## Summary
- Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.
- Ingram is President and CEO of Sarepta, with which Arrowhead has a collaboration agreement from Nov 2024.
- He receives standard non-employee director compensation plus sign-on RSUs of $771,200 vesting over 3 years.
- Ingram is not independent under Nasdaq rules due to the Sarepta collaboration and stock purchase.

## SEC filing metadata
- accession: 0001628280-25-004313
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/0001628280-25-004313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/arwr-20250207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-004313
- JSON: https://secwatch.observer/filing/0001628280-25-004313.json
- Plain text: https://secwatch.observer/filing/0001628280-25-004313.txt

## Key facts
- Executive change
  Douglas Ingram was appointed as director at ARROWHEAD PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: director
  source text: On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828025004313/0001628280-25-004313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.